Emergent Biosolutions (EBS) Stock Price, Quote & News

Company Profile

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax va...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 240 631 3200

Website: www.emergentbiosolutions.com

Address:

300 Professional Drive, Gaithersburg, United States

MoneyGroupLLC Jan. 14 at 6:42 AM

Enter: $EBS Calls Strike Price: $13 Expiry Date: FEB 20 2026 Buy in Price: $0.75 - $0.80 Sell Price: $1.37 Profit : +71% (Turn every $1 into $1.71) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/

0 · Reply

ImmxBeliever Jan. 14 at 3:52 AM

$EBS The definition of Copium 👇👇👇

0 · Reply

KnuckleSandwich Jan. 14 at 2:21 AM

$EBS it’s frustrating to say but we could really use some assistance from Jessica Fye at JPM to lift the weight off of EBS. Imagine what the share price could be if Papa was not fighting a one man uphill battle. Official coverage or preferably an upgrade would launch this rocket to 20++ 💥💪🏼

0 · Reply

ComradeKomisar Jan. 14 at 12:18 AM

$EBS This is how you do a proper share buyback program. Full transparency, no strategic ambiguity. I suspect the strategic ambiguity $EBS opted for has to with the mood of OHA. They can veto any capital return program over $30M. The fact that, in 2025, they paid $100M of debt, committed to purchasing $50M of shares, and $30M of unsecured debt tells me that sustainable free cash flow can be up to $180M /year https://www.globenewswire.com/news-release/2026/01/12/3216745/0/en/Bavarian-Nordic-Transactions-in-Connection-with-Share-Buy-Back-Program.html

0 · Reply

ComradeKomisar Jan. 13 at 11:12 PM

$EBS YTD performance masterpiece. I call it: The shArtening!

1 · Reply

ComradeKomisar Jan. 13 at 11:11 PM

$EBS 🫡

0 · Reply

ComradeKomisar Jan. 13 at 11:10 PM

$EBS The price action has been advised by "The prYce ActiOOn advisOOr"

0 · Reply

billywilliamz Jan. 13 at 11:05 PM

$EBS immx doesn’t beleive in billiam him and nrg7 blocked me my life’s ruined 😞

1 · Reply

billywilliamz Jan. 13 at 10:57 PM

$EBS doPeTions incooming probably going to $9

1 · Reply

ImmxBeliever Jan. 13 at 10:31 PM

$EBS Hi ladies Where are the upper and lowercase letters?

0 · Reply

Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation

Jan 8, 2026, 4:30 PM EST - 5 days ago

Emergent BioSolutions Receives Delivery Order up to $21.5 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War in 2026

Jan 8, 2026, 8:00 AM EST - 5 days ago

Emergent BioSolutions and PANTHER Announce Agreement to Support the Continuation of the Africa CDC-led MpOx Study in Africa

Jan 7, 2026, 7:59 AM EST - 6 days ago

Emergent BioSolutions to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Dec 12, 2025, 8:30 AM EST - 4 weeks ago

Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site

Nov 18, 2025, 8:00 AM EST - 2 months ago

Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access

Nov 12, 2025, 4:01 PM EST - 2 months ago

Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors

Nov 6, 2025, 11:00 PM EST - 2 months ago

Emergent BioSolutions: Solid Q3, Expecting Better Days To Come

Oct 29, 2025, 8:56 PM EDT - 2 months ago

Emergent BioSolutions Inc. (EBS) Q3 2025 Earnings Call Transcript

Oct 29, 2025, 4:15 PM EDT - 2 months ago

Emergent BioSolutions Reports Third Quarter 2025 Financial Results

Oct 28, 2025, 8:00 AM EDT - 2 months ago

Emergent BioSolutions Releases New Survey Findings Revealing Heightened Concerns About Biological Threats and U.S. Preparedness

Oct 8, 2025, 7:45 AM EDT - 3 months ago

Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025

Sep 24, 2025, 4:05 PM EDT - 3 months ago

Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone

Sep 19, 2025, 8:34 AM EDT - 4 months ago

Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner

Sep 15, 2025, 8:35 AM EDT - 4 months ago

Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain

Sep 9, 2025, 7:30 AM EDT - 4 months ago

Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness

Sep 2, 2025, 7:40 AM EDT - 4 months ago

Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use

Aug 29, 2025, 8:05 AM EDT - 4 months ago

Emergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International Overdose Awareness Day

Aug 27, 2025, 8:01 AM EDT - 4 months ago

Emergent BioSolutions to Participate in Upcoming Investor Conferences

Aug 21, 2025, 8:45 AM EDT - 5 months ago

Emergent BioSolutions Supports Voices for Awareness and Facing Fentanyl Now on August 21, 2025 for National Fentanyl Prevention and Awareness Day™

Aug 12, 2025, 12:46 PM EDT - 5 months ago

Emergent BioSolutions: Q2 Results Could Spark A Strong 2025 Rally

Aug 7, 2025, 7:31 PM EDT - 5 months ago

Emergent BioSolutions Inc. (EBS) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 4:15 PM EDT - 5 months ago

Emergent BioSolutions Reports Second Quarter 2025 Financial Results

Jul 28, 2025, 8:50 AM EDT - 6 months ago

Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives

Jul 28, 2025, 8:50 AM EDT - 6 months ago

New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox

Jul 15, 2025, 7:30 AM EDT - 6 months ago

Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 8, 2025, 4:45 PM EDT - 6 months ago

Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts

Jul 2, 2025, 4:05 PM EDT - 6 months ago

Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate

Jun 23, 2025, 8:05 AM EDT - 7 months ago

Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Bolster U.S. Biodefense Supply

Jun 20, 2025, 2:25 PM EDT - 7 months ago

Emergent BioSolutions: Strategic Turnaround Proving Tricky, But I'm Still Hopeful

Jun 20, 2025, 8:13 AM EDT - 7 months ago

Emergent BioSolutions Announces Addition to Russell 3000® Index

Jun 5, 2025, 7:00 AM EDT - 7 months ago

Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies

May 7, 2025, 10:01 PM EDT - 8 months ago

Emergent BioSolutions Inc. (EBS) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:05 PM EDT - 8 months ago

Emergent BioSolutions Reports First Quarter 2025 Financial Results

May 1, 2025, 5:07 PM EDT - 9 months ago

Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health

Apr 22, 2025, 8:00 AM EDT - 9 months ago

Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025

Mar 31, 2025, 8:00 AM EDT - 10 months ago

Emergent BioSolutions Announces Stock Repurchase Program

Mar 20, 2025, 4:30 PM EDT - 10 months ago

Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08

Mar 20, 2025, 8:06 AM EDT - 10 months ago

Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg

Mar 19, 2025, 4:30 PM EDT - 10 months ago

Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International

Mar 18, 2025, 8:00 AM EDT - 10 months ago

Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products

Mar 13, 2025, 8:29 AM EDT - 10 months ago

Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs

Mar 12, 2025, 8:00 AM EDT - 10 months ago

Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates

Mar 10, 2025, 9:14 AM EDT - 11 months ago

Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International

Mar 3, 2025, 7:58 PM EST - 11 months ago

Emergent BioSolutions Inc. (EBS) Q4 2024 Earnings Call Transcript

Mar 3, 2025, 4:23 PM EST - 11 months ago

Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 18, 2025, 8:55 AM EST - 11 months ago

Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

Feb 7, 2025, 8:06 AM EST - 1 year ago

Emergent BioSolutions and Pro Football Legend Emmitt Smith Raise Awareness of Ready to Rescue Campaign Timed to the Big Game in New Orleans

Jan 16, 2025, 8:00 AM EST - 1 year ago

Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)

Jan 14, 2025, 7:53 AM EST - 1 year ago

Emergent BioSolutions: Stock Is A Likely Winner In 2025

MoneyGroupLLC Jan. 14 at 6:42 AM

0 · Reply

ImmxBeliever Jan. 14 at 3:52 AM

$EBS The definition of Copium 👇👇👇

0 · Reply

KnuckleSandwich Jan. 14 at 2:21 AM

0 · Reply

ComradeKomisar Jan. 14 at 12:18 AM

0 · Reply

ComradeKomisar Jan. 13 at 11:12 PM

$EBS YTD performance masterpiece. I call it: The shArtening!

1 · Reply

ComradeKomisar Jan. 13 at 11:11 PM

$EBS 🫡

0 · Reply

ComradeKomisar Jan. 13 at 11:10 PM

$EBS The price action has been advised by "The prYce ActiOOn advisOOr"

0 · Reply

billywilliamz Jan. 13 at 11:05 PM

$EBS immx doesn’t beleive in billiam him and nrg7 blocked me my life’s ruined 😞

1 · Reply

billywilliamz Jan. 13 at 10:57 PM

$EBS doPeTions incooming probably going to $9

1 · Reply

ImmxBeliever Jan. 13 at 10:31 PM

$EBS Hi ladies Where are the upper and lowercase letters?

0 · Reply

alwayzwong Jan. 13 at 9:42 PM

$EBS

0 · Reply

Kazoonova Jan. 13 at 9:28 PM

$EBS Down 10% in 1 week on only bullish news. That’s the EBS price action I know.

1 · Reply

KnuckleSandwich Jan. 13 at 8:26 PM

$EBS bloodbath in broad market but EBS will have a green close...not bad with Papa presentation on deck for tomorrow!

0 · Reply

KnuckleSandwich Jan. 13 at 8:23 PM

$EBS Rocketvax is our friend...more good stuff coming shortly!

0 · Reply

Unicorn2020 Jan. 13 at 7:43 PM

$EBS The end is near. Definitely this year. With the BO @ $16 - $18 everyone shall be happy, including Papa.

2 · Reply

ComradeKomisar Jan. 13 at 7:37 PM

$EBS Deep.

1 · Reply

ComradeKomisar Jan. 13 at 6:50 PM

$EBS

0 · Reply

ComradeKomisar Jan. 13 at 6:47 PM

$EBS the ruling is not really on tariffs. It's on whether POTUS can declare national security emergencies. He can, but there are also other ways to do it.

1 · Reply

ImmxBeliever Jan. 13 at 5:14 PM

$EBS

0 · Reply

alwayzwong Jan. 13 at 5:06 PM

$EBS waiting for scotus ruling on tariffs?

0 · Reply

ImmxBeliever Jan. 13 at 4:09 PM

$EBS The shorts. The shorts Morons

1 · Reply

ComradeKomisar Jan. 13 at 2:58 PM

$EBS Another 200K shares of shArt inventory, has been returned to IBKR's vaults. The January shArt is now 50% 'covered'.

1 · Reply

Market Cap	650.72M
Revenue (ttm)	1.04B
Net Income (ttm)	-190.60M
EPS (ttm)	N/A
PE Ratio	6.55
Forward PE	N/A
Profit Margin	-18.26%
Debt to Equity Ratio	1.14

Volume	669,500
Avg Vol	940,884
Day's Range	N/A - N/A
Shares Out	52.52M
Stochastic %K	25%
Beta	2.30
Analysts	Strong Sell
Price Target	$13.50